Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06472661 · ClinicalTrials.gov registry record · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
A Early Phase 1 study of Advanced Melanoma, sponsored by University of Virginia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT06472661 is a Early Phase 1 study of Advanced Melanoma that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 11 participants, below the 171-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06472661, a Early Phase 1 study of Advanced Melanoma, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment that uses ultrasound waves to heat and destroy tumor tissue, and an injection in the tumor with an experimental drug that activates the immune system called polyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine). Neither the drug nor the device that are used in this study have been approved by the U.S. Food and Drug Administration (FDA).
Conditions Studied
Interventions
- DEVICE Echopulse or Echopulse HD
- DRUG PolyICLC
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2026-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06472661
The ClinicalTrials.gov registry entry for NCT06472661 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (94% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Echopulse or Echopulse HD is the first listed.
NCT06472661 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06472661 about?
NCT06472661 is a clinical study titled "FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma". This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment ...
What is the current status of trial NCT06472661?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2024-09-27. Estimated completion is 2026-08.
What conditions does trial NCT06472661 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT06472661?
The interventions under investigation include: Echopulse or Echopulse HD (DEVICE), PolyICLC (DRUG).
Who is sponsoring clinical trial NCT06472661?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06472661 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RECRUITING · Phase 3
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.